HERTFORDSHIRE, England and PITTSBURGH, Jan. 31, 2019 /PRNewswire/ -- Mylan N.V. (NASDAQ: MYL) today announced the U.S. Food and Drug Administration (FDA) approval of Wixela™ Inhub™ (fluticasone ...

Please provide your email address to receive an email when new articles are posted on . For approval, generic fluticasone-salmeterol was required to be tested in only patients with asthma, not COPD.

The first generic version of the popular Advair asthma inhaler has been approved by U.S. regulators. The Food and Drug Administration on Wednesday approved Mylan’s version in three strengths for ages ...

A generic fluticasone-salmeterol (Wixela Inhub) maintenance inhaler was clinically equivalent to name-brand Advair Diskus for chronic obstructive pulmonary disease (COPD), a propensity score-matched ...

A propensity score-matched cohort study of patients treated for chronic obstructive pulmonary disease (COPD) in routine practice found that the use of generic and brand-name fluticasone–salmeterol was ...

Asthma inhalers can be for quick relief or long-term control. Rescue inhalers work by relaxing your airway muscles to help ...

LONDON (Alliance News) - Shares in Consort Medical PLC fell early Tuesday after the drug delivery company warned that delays to Mylan NV's Wixela inhaler for lung disease treatment will hit annual ...

(AP) -- The first generic version of the popular Advair asthma inhaler has been approved by U.S. regulators. The Food and Drug Administration on Wednesday approved Mylan's version in three strengths ...